NewsRx

Search our medical news database

Cobalis Corp.

Cobalis settles outstanding litigation with Gryphon Master Fund, L.P.

Published in Physician Law Weekly, May 3rd, 2006

Cobalis Corp. (CLSC), a pharmaceutical development company specializing in anti-allergy medications, announced that the company has reached and executed a settlement agreement with Gryphon Master Fund, L.P. of Dallas, TX.

Both Gryphon and Cobalis have further agreed to dismiss any and all current and future claims, legal proceedings and litigation.

The settlement, which relates to two investments in Cobalis totaling $1.6 million that were made by Gryphon in September 2003, includes an agreed judgment totaling a maximum of $1.6 million. Cobalis' judgment amount would be reduced to $1.4 million, provided Cobalis fully pays Gryphon on or before October...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook